Volitionrx Limited (VNRX) Misses Q3 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. FIX
9. TSCO
10. BE

Go back to Volitionrx Limited (VNRX) Misses Q3 EPS by 2c

VolitionRx Announces Third Quarter 2015 Financial Results and Business Update

November 4, 2015 6:30 AM EST

NAMUR, Belgium, Nov. 4, 2015 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced financial results for the third quarter ended September 30, 2015.

Third Quarter 2015 and Recent Company Highlights:

Released interim data from an on-going 4,800-subject double blind clinical trial revealing NuQ® blood tests detect 81% of colorectal cancers (CRC) and 67% of high risk... More